Kane Biotech Valuation

Is KNE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of KNE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate KNE's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate KNE's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for KNE?

Key metric: As KNE is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for KNE. This is calculated by dividing KNE's market cap by their current revenue.
What is KNE's PS Ratio?
PS Ratio	20.9x
Sales	CA$757.11k
Market Cap	CA$15.81m

KNE key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	22.7x
Enterprise Value/EBITDA	-3.8x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does KNE's PS Ratio compare to its peers?

The above table shows the PS ratio for KNE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	18x
AWKN Awakn Life Sciences	68.2x	n/a	CA$5.0m
CSCI COSCIENS Biopharma	2x	n/a	CA$13.3m
MPH Medicure	0.5x	n/a	CA$9.4m
SZLS StageZero Life Sciences	1.2x	n/a	CA$4.9m
KNE Kane Biotech	20.9x	n/a	CA$15.8m

Price-To-Sales vs Peers: KNE is expensive based on its Price-To-Sales Ratio (20.9x) compared to the peer average (18x).

Price to Sales Ratio vs Industry

How does KNE's PS Ratio compare vs other companies in the CA Biotechs Industry?

5 Companies	Price / Sales	Estimated Growth	Market Cap
TH Theratechnologies	0.7x	7.7%	US$54.91m
MBX Microbix Biosystems	1.8x	22.7%	US$29.88m
CSCI COSCIENS Biopharma	2x	n/a	US$9.44m
MPH Medicure	0.5x	n/a	US$6.68m

5 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: KNE is expensive based on its Price-To-Sales Ratio (20.9x) compared to the North American Biotechs industry average (9.2x).

Price to Sales Ratio vs Fair Ratio

What is KNE's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

KNE PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	20.9x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate KNE's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Medexus Pharmaceuticals

CA$58.7m

Operates as a pharmaceutical company in Canada and the United States.

MDP

CA$2.38

12.8%

60.8%

Verano Holdings

CA$722.2m

Operates as a vertically integrated multi-state cannabis operator in the United States.

VRNO

CA$1.98

-17.2%

-65.9%

Cresco Labs

CA$525.4m

Cresco Labs Inc., together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States.

CA$1.67

-8.2%

-27.7%